国际口腔医学杂志2024，Vol.51Issue(1)：21-27,7.DOI:10.7518/gikq.2024021
程序性死亡受体/配体免疫治疗策略在人乳头瘤病毒阳性头颈部鳞状细胞癌中的研究进展
Progress in research into programmed death-1/programmed death-ligand 1 immunotherapy strategies in human papillomavirus-positive head and neck squamous cell carcinoma
摘要
Abstract
Human papillomavirus(HPV)infection has become one of the main pathogenic factors of head and neck squamous cell carcinoma(HNSCC).The expression levels of various immune cells and effector molecules,including pro-grammed death(PD)-1 and programmed death-ligand 1,are higher in HPV-positive HNSCC samples than in HPV-nega-tive samples.Furthermore,patients with HPV-positive HNSCC and high PD-1 or PD-L1 expression showed significantly improved survival.Moreover,patients with HPV-positive HNSCC and on anti-PD-1/PD-L1 immunotherapy showed hi-gher objective remission rate(ORR),progression-free survival(PFS),overall survival(OS)and other indicators than pa-tients with HPV-negative HNSCCs,suggesting that the former received greater clinical benefits than the latter.In addi-tion,HPV cancer vaccine combined with PD-1/PD-L1 inhibitors,dual pathway inhibitors and other immunotherapy regi-mens play distinct beneficial roles in HPV-related cancer.Therefore,tailoring immunotherapy to patients based on HPV status is a promising treatment strategy.关键词
头颈部鳞状细胞癌/人乳头瘤病毒/程序性死亡受体/配体/免疫治疗Key words
head and neck squamous cell carcinoma/human papillomavirus/programmed death-1/programmed death-ligand 1/immunotherapy分类
医药卫生引用本文复制引用
刘世一,陈中,张素欣..程序性死亡受体/配体免疫治疗策略在人乳头瘤病毒阳性头颈部鳞状细胞癌中的研究进展[J].国际口腔医学杂志,2024,51(1):21-27,7.基金项目
Geriatric Disease Prevention and Control Project of Hebei Provincial Health Commission(13000022-PO0860410186E) （13000022-PO0860410186E）
Key Science and Technology Research Program of Hebei Province(20190695) 河北省卫生健康委员会老年病防治项目(13000022PO0860-410186E) （20190695）
河北省医学科学研究课题计划(20190695) （20190695）
